The company has received final approval from the US Food and Drug Administration (USFDA) for its Tobramycin Inhalation Solution, the Mumbai-based company said in a statement.
The drug is indicated for management of cystic fibrosis patients.
As per IMS MAT December 2016 sales data, Tobramycin inhalation solution had sales of $133.6 million in the US market.
The stock on Thursday closed 1.58 per cent higher at Rs 1,490 on BSE.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)